Everything below concerns Cyclic heptapeptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-01-15. Where a claim depends on a specific study, the study is described rather than over-claimed.
After subcutaneous administration, plasma concentrations rise within roughly thirty minutes and the elimination half-life is short, on the order of two to three hours. Reported physiological responses include transient increases in blood pressure and nausea, which tended to diminish with repeated dosing in trial settings. Because the peptide clears quickly, effects are not expected to persist long after a dose. Absorption from non-injected routes is poorly characterised, and nasal delivery produced variable plasma levels in older work.
Clinical research typically uses randomised, double-blind, placebo-controlled designs. The most common primary endpoint is the desire domain score of the Female Sexual Function Index, sometimes paired with a distress measure. Secondary outcomes include arousal, satisfaction, and event-based counts of satisfying sexual episodes. Across trials, average improvements are modest and individual responses vary widely. Whether benefits persist beyond a few months, and whether they depend on baseline hormone status, remain open questions rather than settled findings.
Melanocortin receptors form a family of five G-protein-coupled receptors designated MC1 through MC5. Bremelanotide binds most strongly at MC4R and MC1R, with weaker activity reported at MC3R and MC5R. MC4R is expressed in hypothalamic nuclei that coordinate energy balance and aspects of sexual behaviour. The prevailing interpretation is that central MC4R activation, rather than peripheral vascular effects alone, drives the reported changes in desire. This account remains partly inferential, since direct receptor-level measurement in living humans is not practical.
Whether the behavioral effect originates centrally, peripherally, or through both remains an active question. Animal experiments using receptor antagonists and site-specific injections point toward hypothalamic melanocortin circuits as a key locus, but translating those findings to humans is not straightforward. Blood pressure changes observed in trials suggest a vascular component that may be peripherally mediated. The relationship between receptor occupancy and reported effect has not been mapped in humans, and no validated biomarker predicts response. This gap makes it difficult to explain individual variability on pharmacological grounds alone.
Bremelanotide acts as an agonist at melanocortin receptors, a family of five G-protein-coupled receptors labeled MC1 through MC5. Binding studies indicate activity at several of these subtypes rather than strict selectivity for one. Signalling proceeds mainly through Gs-mediated activation of adenylyl cyclase, raising intracellular cyclic AMP. The MC4 receptor, expressed in hypothalamic and limbic circuits, is widely regarded as the subtype most relevant to sexual response. Because the molecule is not subtype-selective, effects at other melanocortin receptors are expected and are used to explain some observed side effects.
The peptide contains seven amino acids arranged in a ring, closed by a lactam bridge between a side-chain acid and an amine. This cyclic constraint holds the backbone in a defined conformation and increases resistance to enzymatic breakdown relative to linear analogs. N-terminal acetylation and a C-terminal amide further protect the molecule from exopeptidases. The result is a compound with a comparatively long circulation time for a small peptide. Structural modification of the bridge alters receptor affinity, which is one reason analogs in this family differ in their subtype preferences.
| Property | Value | Notes |
|---|---|---|
| Primary receptor targets | MC4R and MC1R | Agonist activity; MC3R and MC5R weaker |
| Route studied in trials | Subcutaneous injection | Intranasal form was not approved |
| Elimination half-life | Approximately 2–3 hours | Short relative to the dosing interval |
| Common analytical method | Liquid chromatography–tandem mass spectrometry | Used for peptide quantification in plasma |
| Reported adverse events | Nausea, flushing, headache | Transient blood pressure rise also noted |
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
Across literature and commercial listings, the substance appears under several names, including bremelanotide, PT-141, and various brand designations. A CAS registry number provides a unique identifier for the compound, aiding retrieval from chemical databases. Synonym lists may also contain early development codes and descriptive chemical names. When consulting sources, researchers need to confirm that the cited names refer to the same molecular structure to avoid confusion. Naming consistency matters especially when comparing analytical data across publications.
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
The molecular backbone consists of seven amino acid residues joined into a ring through a disulfide bridge. This cyclic conformation is critical for receptor binding. The sequence includes an acetylated N-terminus and an amidated C-terminus, modifications that improve resistance to enzymatic breakdown. One residue is in the D-configuration, a feature that further stabilizes the peptide against protease activity. Together, the ring structure and specific stereochemistry determine selectivity among melanocortin receptor subtypes.
Bremelanotide acts as an agonist at several melanocortin receptors, with the strongest reported activity at MC4R and measurable activity at MC1R and MC3R. Because MC4R is expressed in hypothalamic and limbic circuits, the proposed mechanism links receptor activation to modulation of central pathways involved in desire rather than to direct effects on peripheral genital tissue. The precise downstream steps remain incompletely characterized, and evidence for the involvement of specific neurotransmitters is suggestive rather than settled. Nausea and blood pressure elevation reported during trials are consistent with melanocortin signaling outside the intended target circuit.
Compared with melanotan II, bremelanotide is a smaller cyclic peptide with a more constrained backbone, which affects receptor selectivity and metabolic stability. Published descriptions give a plasma half-life on the order of a few hours after subcutaneous administration, with elimination through hepatic and renal routes and limited plasma protein binding. Central access is inferred from effects observed in animal models, although direct measurement in humans is limited. Handling and storage requirements follow from the peptide backbone, which is susceptible to hydrolysis and oxidation.
The melanocortin system comprises five G protein-coupled receptors, designated MC1 through MC5, that signal mainly through cyclic AMP accumulation. MC1R and MC2R are associated with pigmentation and adrenal steroid production, while MC3R and MC4R are expressed in the central nervous system and influence energy balance and behavior. MC5R appears in exocrine tissues. Natural agonists include alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone, and endogenous antagonists such as agouti-related protein modulate the same sites. This receptor family provides the framework within which bremelanotide activity is described.
Darshan Ranganathan (4 June 1941 – 4 June 2001) was an organic chemist from India who was known for her work in bio-organic chemistry, including "pioneering work in protein folding." She was also recognized for her work in "supramolecular assemblies, molecular design, chemical simulation of key biological processes, synthesis of functional hybrid peptides and synthesis of nanotubes."
==== Non-synthesizers ==== Some mammals have lost the ability to synthesize vitamin C, including simians and tarsiers, which together make up one of two major primate suborders, Haplorhini. This group includes humans. The other more primitive primates (Strepsirrhini) have the ability to make vitamin C. Synthesis does not occur in some species in the rodent family Caviidae, which includes guinea pigs and capybaras, but does occur in other rodents, including rats and mice. Synthesis does not occur in most bat species, but there are at least two species, frugivorous bat Rousettus leschenaultii and insectivorous bat Hipposideros armiger, that retain (or regained) their ability of vitamin C production. A number of species of passerine birds also do not synthesize, but not all of them, and those that do not are not clearly related; it has been proposed that the ability was lost separately a number of times in birds. In particular, the ability to synthesize vitamin C is presumed to have been lost and then later re-acquired in at least two cases. The ability to synthesize vitamin C has also been lost in about 96% of extant fish (the teleosts). Schistosomes (parasitic flatworms) cannot synthesize vitamin C and require it from their hosts in order to produce eggs; in both guinea pigs and in mice genetically engineered to be non-synthesizers, vitamin C deficiency prevents schistosomes from reproducing. In mice, it has additionally been found that vitamin C deficiency (even intermittent) prevents schistosomes from causing disease.
In 2013 for the population aged 40-80 years, the global prevalence of glaucoma was estimated at 3.54%, thus affecting 64.3 million worldwide. The same year, 2.97 million people in North America had open-angle glaucoma. By 2040, the prevalence of all types of glaucoma was projected to increase to 111.82 million worldwide and to 4.72 million in North America. Globally, glaucoma is the second-leading cause of blindness, while cataracts are a more common cause. In the United States, glaucoma is a leading cause of blindness for African Americans, who have higher rates of primary open-angle glaucoma, and Hispanic Americans. Bilateral vision loss can negatively affect mobility and interfere with driving. A meta-analysis published in 2009 found that people with primary open-angle glaucoma do not have increased mortality rates or increased risk of cardiovascular death. A 2024 JAMA Ophthalmology article reports that in 2022, an estimated 4.22 million people in the U.S. had glaucoma, with 1.49 million experiencing vision impairment due to the condition, according to a meta-analysis. The study found that Black adults were about twice as likely to be affected by glaucoma as White adults. Glaucoma prevalence was 1.62% among individuals aged 18 and older and 2.56% among those aged 40 and older, while vision-affecting glaucoma occurred in 0.57% and 0.91% of these age groups, respectively.
=== Vascular endothelium and microangiopathy === An upregulation of vascular cell adhesion molecule-1 is observed in NL tissue, indicating leukocyte aggregation and an inflammatory response. Furthermore, there is a reduced VEGF expression along with AGE-mediated cross-linking, reducing ECM fluidity. Both factors impair new vessel growth, lead to poor oxygenation, and impair tissue healing.
== Research == In both autoimmune and inflammatory diseases, the condition arises through aberrant reactions of the human adaptive or innate immune systems. In autoimmunity, the patient's immune system is activated against the body's own proteins. In chronic inflammatory diseases, neutrophils and other leukocytes are constitutively recruited by cytokines and chemokines, resulting in tissue damage. Mitigation of inflammation by activation of anti-inflammatory genes and the suppression of inflammatory genes in immune cells is a promising therapeutic approach. There is a body of evidence that once the production of autoantibodies has been initialized, autoantibodies have the capacity to maintain their own production.
Sources: en.wikipedia.org
Natural nitrogen (7N) consists of two stable isotopes: the vast majority (99.62%) of naturally occurring nitrogen is nitrogen-14, with the remainder (0.38%) being nitrogen-15. Thirteen radioisotopes are also known, with atomic masses ranging from 9 to 23, along with three nuclear isomers. All of these radioisotopes are short-lived, the longest-lived being 13N with a half-life of 9.965 minutes. All of the others have half-lives shorter than ten seconds. Isotopes lighter than the stable ones generally decay to isotopes of carbon, and those heavier beta decay to isotopes of oxygen. Nitrogen-13 is a positron emitter and one of the main isotopes used in medical PET scans.
== Metabolism == When evaluated by in vitro studies, the metabolism of dalbavancin was minimally impacted by the human hepatic CYP450 system. Further investigations with either inducers or inhibitors of this enzyme system demonstrated no changes in the elimination or clearance of dalbavancin, and the metabolism of model compounds of these CYP systems was not altered by the dalbavancin. Hydroxy-dalbavancin, a minor metabolite that has only been identified in urine, was also not changed in its formation or elimination with these enzyme models.
skin rash itching abnormal hair loss upset stomach vomiting loss of taste abnormal sensations (tingling, prickling, burning, tightness, and pulling) swelling joint and muscle pain drowsiness dizziness decreased platelet count (thrombocytopenia) aplasia cutis congenita (prenatal exposure) thyroid gland enlargement (prenatal exposure) choanal atresia (prenatal exposure during the first trimester of pregnancy) acute pancreatitis
The same number of families will be uprooted, business inconvenienced or lost, and farms destroyed . . .mudflats [from reservoir drawdowns] would still blight the land that now provides a classic definition of nature's beauty." He proposed legislation authorizing the Army Corps of Engineers to discover the "recreational, conservation, and preservation uses" of the river in 1972 and 1973. Then, in 1974, he introduced a House Bill that would designate the river part of the National Wild and Scenic Rivers System (NWSRS). North Carolina Senators Sam Ervin and Jesse Helms introduced a parallel bill that passed the Senate, but the House Bill stalled. It was not until 1976 that Congress would amend the Wild and Scenic Rivers Act, adding 26.5 miles of the river to the NWSRS and effectively thwarting the Blue Ridge Power Project. Also in 1974, Mizell proposed an amendment to the Legal Services Corporation Act, preventing the proposed government agency from handling desegregation suits. The amendment was included in the final version of the bill which passed. He was an opponent of desegregation busing as well, stating "Quality education...cannot be achieved while overwhelming additional expenses and administrative duties are required to implement court-ordered busing." The Watergate scandal affected Republican House members in 1974, and Mizell was upset by Democrat Stephen L. Neal, 64,634 (52.4 percent) to 59,182 (47.6 percent). Mizell had been considering running for the Senate to replace Ervin, but he opted to run for the House again, considering this a safer election bet.
=== Writing === During an interview at the Deadline Hollywood, Kripke teased that the season would be exploring Vought's past to explore the myths surrounding the company and the United States in general, as the comics also explored flashbacks focused during World War II and the Vietnam War and wanted to explore over how the superhero phenomenon did not only altered the present but also parts from the past as well, while also exploring over how the politics can turn neighbors against each other and what actually means to be in America. He revealed that this was one of the reasons of introducing Soldier Boy in the season, since the history of Vought and the US was explored through the character given that he was the first superhero ever and has been around since the Second World War. Kripke revealed that the toxic masculinity would be the real-life issue of the season and would also show how it would be affecting the main characters after many of them are pushed to the limit. He detailed over how the toxic masculinity was an ongoing issue that as by today continues affecting the lives of a lot of men, with many of them being targeted for not being considered ‘manly’ enough and over how this becomes very destructive to the society and organizations. This was the main reason of Soldier Boy being introduced as he represents the embodiment of the toxic masculinity which is an issue that the world still faces thanks to the older generations.
Sources: en.wikipedia.org
Register of Francis Crick Personal Papers – MSS 660 Crick's personal papers at Mandeville Special Collections Library, Geisel Library, University of California, San Diego Francis Crick Archive — Papers by Francis Crick are available for study at the Wellcome Library's Archives and Manuscripts department. These papers include those dealing with Crick's career after he moved to the Salk Institute in San Diego. The digitised papers are available at Codebreakers: Makers of Modern Genetics: the Francis Crick papers Comprehensive list of pdf files of Crick's papers from 1950 to 1990 – National Library of Medicine. Francis Crick papers – Nature.com Key Participants: Francis H. C. Crick – Linus Pauling and the Race for DNA: A Documentary History Audio and video files
Marc Laidlaw is an American writer. Between 1997 and 2016, he was a writer for the video game company Valve, where he worked on the Half-Life and Portal series. Before joining Valve, Laidlaw was a novelist working in fantasy and horror. In 1996 he won the International Horror Guild Award for his novel The 37th Mandala. In 2025, Laidlaw's 1983 short story "400 Boys" was adapted as an episode of the Netflix series Love, Death & Robots.
Summarising their findings, they conclude: "The medical notes indicate that, on admission, Dylan's bronchial disease was found to be very extensive, affecting upper, mid and lower lung fields, both left and right." The forensic pathologist, Bernard Knight, who examined the post-mortem report, concurs: "death was clearly due to a severe lung infection with extensive advanced bronchopneumonia...the severity of the chest infection, with greyish consolidated areas of well-established pneumonia, suggests that it had started before admission to hospital." Thomas died at noon on 9 November 1953, having never recovered from his coma. A nurse, and the poet John Berryman, were present with him at the time of death.
== Arrival in Spain == In Madrid, Alexander von Humboldt pursued the idea of a scientific expedition to Spanish America, despite the usual restrictions on foreign travel in Spanish colonies. Through the assistance of Don Mariano Luis de Urquijo, Spain’s First Secretary of State, whom Humboldt had previously met in London, he was introduced to King Charles IV of Spain. The king granted Humboldt and his companion, Aimé Bonpland, official permission to travel throughout Spanish America for scientific purposes. The royal passports granted Humboldt and Bonpland extensive rights, including the use of scientific instruments, freedom of movement, and the authority to conduct research throughout Spanish territories. Colonial officials were instructed to assist them as needed. Such privileges were exceptional, given that Spain had historically allowed very few foreign scientific missions in its colonies, due to longstanding policies of restricting access to outsiders for reasons of state security, economic monopoly, and religious protection. The level of trust and freedom granted to Humboldt was unprecedented for a non-Spaniard. Humboldt recognized that Spain’s primary interest in granting permission was related to his expertise in mineralogy and the potential for discovering new mineral resources, rather than purely scientific advancement.
Mister Donut specializes in coffee and doughnuts. However, it also serves a wide variety of other foods, such as hamburgers and noodle soups. As of 2004, the first Mister Donut shop opened in Taiwan, featuring "doughnuts in 50 different flavors every day. Each flavor comes with a label indicating the level of sweetness." The store also sold around 15 kinds of drinks and beverages. In 2007, Mister Donut attracted media attention in Japan when it admitted it had used out-of-date syrups in some of its drinks earlier that year.
Sources: en.wikipedia.org
Trial results generally show a small to moderate average improvement in desire scores relative to placebo. The distribution of responses is wide, and some participants show little measurable change. Group averages should not be read as a prediction for any single person.
Nausea, flushing, headache, and transient blood pressure elevation are the most frequently reported events. These typically appear shortly after dosing and are usually described as mild to moderate in severity. Safety data covering long periods of continuous use remain limited.
A short half-life means the compound clears from circulation within hours, so any effect is tied closely to dosing time. Accumulation between doses is therefore unlikely under the studied schedule. The practical consequence is that timing of administration shapes what observers record.
It is frequently described as an MC4 receptor agonist, but binding assays show activity at more than one melanocortin subtype. Selectivity is therefore relative rather than absolute. This matters when interpreting side effects tied to other receptor subtypes.